novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Andexanet Alfa for the Reversal od Factor Xa Inhibitor Activity

23 Novembro 2015

Deborah M. Siegal et al. New Engl J Med 2015

DOI: 10.1056/NEJMoa1510991

Tags:
Antitrombóticos

Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database

23 Novembro 2015
0

Peri-procedural management of patients taking oral anticoagulants

23 Novembro 2015
0